In rats with congestive heart failure, long-term treatment with ivabradine decreased heart rate by 18% versus untreated controls, improving left ventricular function and stroke volume.
Does ivabradine improve left ventricular function and intrinsic myocardial structure in rats with congestive heart failure?
In a rat model of heart failure, long-term heart rate reduction with ivabradine improves LV function and induces beneficial structural modifications in the myocardium.
BACKGROUND: Heart rate reduction (HRR) improves left ventricular (LV) filling, increases myocardial O2 supply, and reduces myocardial O2 consumption, which are all beneficial in congestive heart failure (CHF). However, the long-term effects of HRR on cardiac function and remodeling are unknown. METHODS AND RESULTS: We assessed, in rats with CHF, the effects of long-term HRR induced by the selective I(f) current inhibitor ivabradine (as food admix for 90 days starting 7 days after coronary artery ligation). To assess intrinsic modifications of LV tissue induced by long-term HRR, all parameters were reassessed 3 days after interruption of treatment. Ivabradine decreased heart rate over the 90-day treatment period (-18% versus untreated at 10 mg x kg(-1) x d(-1)), without modifying blood pressure, LV end-diastolic pressure, or dP/dt(max/min). Ivabradine significantly reduced LV end-systolic but not end-diastolic diameter, which resulted in preserved cardiac output due to increased stroke volume. In the Langendorff preparation, ivabradine shifted LV systolic but not end-diastolic pressure-volume relations to the left. Ivabradine decreased LV collagen density and increased LV capillary density without modifying LV weight. Three days after interruption of treatment, the effects of ivabradine on LV geometry, shortening, and stroke volume persisted despite normalization of heart rate. CONCLUSIONS: In rats with CHF, long-term HRR induced by the selective I(f) inhibitor ivabradine improves LV function and increases stroke volume, preserving cardiac output despite the HRR. The improvement of cardiac function is related not only to the HRR per se but also to modifications in the extracellular matrix and/or function of myocytes as a consequence of long-term HRR.
Mulder et al. (Tue,) conducted a other in Congestive heart failure. Ivabradine vs. Untreated was evaluated on Heart rate, left ventricular function, and intrinsic myocardial structure. In rats with congestive heart failure, long-term treatment with ivabradine decreased heart rate by 18% versus untreated controls, improving left ventricular function and stroke volume.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: